Research
Poster presentation at Thrombosis and Hemostasis Summit of North America 2024, Chicago, IL April 4, 2024. Poster Num: 319 Title: Overcoming distance and travel barriers for Virginia Bleeding Disorders Treatment Centers: A Comprehensive Needs Assessment. Erika Martin, Lauren Dunn, Katherine Bains, Jan Kuhn.
Poster presentation at Thrombosis and Hemostasis Summit of North America 2024, Chicago, IL April 5, 2024. Poster Num: 406 Title: Surgical and procedural outcomes for patients with factor VIII deficiency taking Emicizumab prophylactically: A regional approach to data collection and analysis. Janice Kuhn, Regina Butler, Lisa Maiale-Howell, Colleen Druzgal, Margy Sennett.
Edwards JV, Prevost NT, Hinchliffe DJ, Nam S, Chang SC, Hron RJ, Madison CA, Smith JN, Dixon K, Poffenberger CN, Taylor MM, Martin EJ. Preparation and Activity of Dressings Designed for Prolonged Field Care Use: Hemostatic and Antibacterial Properties of Greige Cotton/Zeolite Formularies comparing Silver and Ascorbic Acid Finishes. Int J Mol Sci. 2023 Dec 4;24(23):17115. doi: 10.3390/ijms242317115. PMID: 38069435; PMCID: PMC10706952.
Das K, Pendurthi UR, Manco-Johnson M, Martin EJ, Brophy DF, Mohan Rao LV. Factor VIIa Treatment Increases Circulating Extracellular Vesicles in Hemophilia Patients: Implications for the Therapeutic Hemostatic Effect of FVIIa. Journal of Thromb Haemostasis 20:8 August 2022 https://pubmed.ncbi.nlm.nih.gov/35608928
Poster presentation at ATHN Data Summit 2022, Virtual Meeting October 19-21, 2022. Title: Using Community Count Data to Calculate Hemophilia Prevalence and consider access to HTC Care. Erika J. Martin, Lauren Dunn, Jan Kuhn.
Poster presentation at World Federation of Hemophilia World Congress 2022, Virtual Conference. Poster Num: PO-35 Title: A comparison of adult to pediatric hemostatic response to emicizumab therapy within the same institution. Erika J. Martin, Jan Kuhn, Melinda Nolte, Gita V. Massey.
Benjamin J Samelson-Jones, Christine Guelcher, Jan Kuhn, Regina Butler, Gita Massey, Michael F Guerrera, Leslie Raffini. Real-world cost estimates of initiating emicizumab in US patients with haemophilia A. Haemophilia. 2021 Jul;27(4):591-598.
Martin EJ, Nolte ME, Kuhn J, Schmidt N, Pfaff N, Brophy DF. An in vitro pharmacodynamic spiking study of befovacimab, a tissue factor pathway inhibitor monoclonal antibody, in blood samples from patients with severe FVIII deficiency. Haemophilia 2021 27:4 https://pubmed.ncbi.nlm.nih.gov/33915599 doi: 10.1111/hae.14314
Simmons GL, Sabo RT, Martin EJ, Brophy DF, Aziz M, Hawks K, Fisher BJ; Natarajan R, Roberts CH, Fowler AA 3rd, Toor AA. Safety and Tolerability of Intra-venous Ascorbic Acid in Allogeneic Hematopoietic Cell Transplant Recipients: A Matched Historical Control Study. Eur J Haematol. 2021.
Enoksson M, Martin EJ, Holmberg H, Jensen MS, Kjelgaard-Hansen M, Egebjerg T, Buchardt J, Krogh TN, Demuth H, Sanfridson A, Hilden I, Kjalke M, Brophy DF. Enhanced potency of recombinant factor VIIa with increased affinity to activated platelets. J Thromb Haemost. 2020 Jan;18(1):104-113. doi: 10.1111/jth.14644. Epub 2019 Oct 14. PMID:31549480
Oral presentation at Mid-Atlantic Region III HTCs Annual Meeting 2020, Virtual Meeting, April 2, 2020. Emicizumab Prophylactic Therapy in Patients with Hemophilia A is better measured by thrombin generation assay than thromboelastography. Erika J Martin, MT Jan Kuhn, MPH, Gita Massey, MD.
McCary I, Guelcher C, Kuhn J, Butler R, Massey G et al. Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. Haemophilia. 2020 Jul;26(4):631-636. doi: 10.1111/hae.14005. Epub 2020 Apr 20.
Oral presentation at Thrombosis and Hemostasis Summit of North America 2020, Chicago, IL October 27, 2020. Poster Num: 246 The influence of Emicizumab (Emi) on global hemostasis is better measured by thrombin generation assay (TGA) than thromboelastography. Erika J Martin, MT Jan Kuhn, MPH, Gita Massey, MD.
Poster presentation at Thrombosis and Hemostasis Summit of North America 2020, Virtual Summit, October 27, 2020. Poster Num: 249 Title: Endogenous thrombin potential (ETP) is significantly more enhanced by Emicizumab in thrombin generation assay (TGA) performed with platelet rich plasma (PRP) as opposed to platelet poor plasma (PPP). Erika J Martin, MT Jan Kuhn, MPH, Gita Massey, MD.
Poster presentation at International Society on Thrombosis and Haemostasis Congress 2020, Virtual Congress, October 27, 2020. Poster Num: PB0822 Title: Emicizumab prophylactic therapy in patients with hemophilia A is better measured by thrombin generation assay than by thromboelastography. Erika J Martin, MT Jan Kuhn, MPH, Don Brophy, PharmD.
Trankle C, Vo C, Martin E, Puckett L, Siddiqui M, Brophy D, Stravitz R, Guzman L. Clopidogrel Responsiveness in Patients with Decompensated Cirrhosis of the Liver Undergoing Pre-Transplant Percutaneous Coronary Interventions. JACC Cardiovasc Interv. 2020 Mar 9;13(5):661-663. doi: 10.1016/j.jcin.2019.08.038. Epub 2019 Dec 25. PMID: 31883726
Martin EJ Barrett JC Nolte ME Kuhn J Brophy DF. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia 2019 Sep;25(5):797-806 doi: 10.1111/hae.13820
Poster presentation at HTRS/NASTH 2019 Scientific Symposium, New Orleans, LA May 10, 2019. Poster Title: Use of Global Assays to Monitor Emicizumab Prophylactic Therapy in Patients with Hemophilia A with Inhibitors. Don Brophy, PharmD Erika J Martin, MT Jan Kuhn, MPH.
Oral presentation at Mid-Atlantic Region III HTCs Annual Meeting 2019, Alexandria, VA, March 15, 2019. The Use of Global Assays to Monitor Emicizumab Prophylactic Therapy in Patients with Hemophilia A with Inhibitors. Erika J Martin, MT Jan Kuhn, MPH.
Al-Horani RA, Abdelfadiel EI, Afosah DK, Morla S, Sistla JC, Mohammed B, Martin EJ, Sakagami M, Brophy DF, Desai UR. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding. J Thromb Haemost. 2019 Dec;17(12):2110-2122. doi: 10.1111/jth.14606. Epub 2019 Sep 10. PMID:31397071
Patel-Hett S, Martin EJ, Mohammed BM, Rakhe S, Sun P, Barrett JC, Nolte ME, Kuhn J, Pittman DD, Murphy JE, Brophy DF. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019 Sep;25(5):797-806. doi: 10.1111/hae.13820. PMID: 31336410
St John AE, Newton JC, Martin EJ, Mohammed BM, Contaifer D Jr, Saunders JL, Brophy GM, Spiess BD, Ward KR, Brophy DF, López JA, White NJ. Platelets retain inducible alpha granule secretion by P-selectin expression but exhibit mechanical dysfunction during trauma-induced coagulopathy. J Thromb Haemost. 2019 May;17(5):771-781. doi: 10.1111/jth.14414. Epub 2019 Mar 18. PMID: 30784176
Liebrecht LK, Newton J, Martin EJ, Wickramaratne N, Jayaraman S, Han J, Aboutanos M, Brophy DF, Mangino MJ. Effects of a novel low volume resuscitation solutions on coagulation and platelet function. PLoS One. 2019 May 1;14(5): e0215386. doi: 10.1371/journal.pone.0215386. eCollection 2019. PMID: 31042735
Brophy DF, Martin EJ, Kuhn J. Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors. Haemophilia. 2019 Mar;25(2): e121-e123. doi: 10.1111/hae.13689. Epub 2019 Feb 12. PMID: 30748061
Liebrecht LK, Newton J, Martin EJ, Wickramaratne N, Jayaraman S, Han J, Aboutanos M, Brophy DF, Mangino MJ. Thromboelastographic analysis of novel polyethylene glycol based low volume resuscitation solutions. PLoS One. 2018 Nov 15;13(11): e0207147. doi: 10.1371/journal.pone.0207147. eCollection 2018. PMID: 30439979
Kuhn J, Noda C, Massey GV. Successful multi-modal immune tolerance induction for factor IX deficiency with inhibitors and allergic reactions. Haemophilia. 2018 May;24(3): e133-e136. doi: 10.1111/hae.13457. Epub 2018 Mar 30. PMID: 29600592.
Poster presentation at International Society on Thrombosis and Haemostasis Congress 2017, Berlin, Germany, July 10, 2017. Poster Num: 1124 Title: A monoclonal antibody with TFPI neutralizing activity improves the coagulation parameters of hemostatic assays performed with hemophilic whole blood. Patel-Hett S, Martin EJ, Rakhe S, Sun P, Pittman DD, Mohammed DM, Nolte M, Kuhn J, Barrett JC, Brophy DF. Murphy JE.
Brophy DF, Martin EJ, Mohammed BM, Barrett JC, Kuhn JG, Nolte ME, Weinberg B, Holmberg HL, Lund J, Salbo R, Waters EK. Modulation of the activated protein C pathway in severe haemophilia A patients: The effects of thrombomodulin and a factor V-stabilizing fab. Haemophilia. 2017 Nov;23(6):941-947. doi: 10.1111/hae.13300. Epub 2017 Jul 27.
Contaifer D Jr, Carl DE, Warncke UO, Martin EJ, Mohammed BM, Van Tassell B, Brophy DF, Chalfant CE, Wijesinghe DS. Unsupervised analysis of combined lipid and coagulation data reveals coagulopathy subtypes among dialysis patients. J Lipid Res. 2017 Mar;58(3):586-599. doi: 10.1194/jlr. P068833. Epub 2016 Dec 19.
Mohammed BM, Sanford KW, Fisher BJ, Martin EJ, Contaifer D Jr, Warncke UO, Wijesinghe DS, Chalfant CE, Brophy DF, Fowler III A, Natarajan R. Impact of high dose vitamin C on platelet function. World J Crit Care Med. 2017 Feb 4;6(1):37-47. doi: 10.5492/wjccm. v6.i1.37. eCollection 2017 Feb 4.
White NJ, Wang Y, Fu X, Cardenas JC, Martin EJ, Brophy DF, Wade CE, Wang X, St John AE, Lim EB, Stern SA, Ward KR, López JA, Chung D. Post-translational oxidative modification of fibrinogen is associated with coagulopathy after traumatic injury. Free Radic Biol Med. 2016 Jul; 96:181-9. doi: 10.1016/j.freeradbiomed.2016.04.023. Epub 2016 Apr 20.
Mehta AY, Mohammed BM, Martin EJ, Brophy DF, Gailani D, Desai UR. Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin. J Thromb Haemost. 2016 Apr;14(4):828-38. doi: 10.1111/jth.13254. Epub 2016 Feb 16.
Lastrapes KK, Mohammed BM, Mazepa MA, Martin EJ, Barrett JC, Massey GV, Kuhn JG, Nolte ME, Hoffman M, Monroe DM, Brophy DF. Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection? Haemophilia. 2016 Jan;22(1):148-51. doi: 10.1111/hae.12844. Epub 2015 Nov 11.
Mohammed BM, Contaifer D Jr, Lastrapes KK, Martin EJ, Mazepa MA, Hoffman M, Monroe DM, Brophy DF. Coated platelet assay: a feasible approach to a complicated science. Haemophilia. 2016 Jan;22(1): e67-70. doi: 10.1111/hae.12845. Epub 2015 Nov 26.
Poster presented at World Federation of Hemophilia World Congress 2016, Orlando, FL July 27, 2016. Poster Num: 160 -PP-W Title: Diagnosis of platelet disorders despite normal platelet aggregations. Janice Kuhn, Melinda Nolte, Erika J. Martin, Gita V. Massey, William Gunning.
Poster presented at World Federation of Hemophilia World Congress 2016, Orlando, FL July 27, 2016. Poster Num: 097-PP-M Title: PF-06741086, a monoclonal antibody with Tissue Factor Pathway Inhibitor (TFPI) neutralizing activity, improves coagulation parameters in global hemostatic assays in hemophilic whole blood and plasma. Sunita Patel-Hett, Erika J. Martin, Bassem M. Mohammed, Swapnil Rakhe, Melinda Nolte, Janice Kuhn, J. Christian Barrett, Debra D. Pittman, Donald Brophy, John E. Murphy
Poster presentation at 7th Haemophilia Global Summit, Madrid, Spain, September 25, 2016. PF-06741086, a monoclonal antibody with Tissue Factor Pathway Inhibitor (TFPI) neutralizing activity, improves coagulation parameters in global hemostatic assays in hemophilic whole blood and plasma. Hett SP, Martin EJ, Mohammed BM, Nolte M, Kuhn J, Barrett JC, Pittman DD, Murphy JE, Brophy DF.
Poster presentation at 2016 American Association of Blood Banks. San Francisco, CA. October 23, 2016. Extended platelet storage: Is Vitamin C the answer? Mohammed BM, Fisher BJ, Martin EJ, Wijesinghe DS, Chalfant CE, Brophy DF, Fowler AA III, Sanford K, Natarajan R.
Salinas V, Carmona R, Mohammed BM, Martin EJ, Brophy DF, Young G. Is some better than none: Are TEG and TGA profiles different in severe FVIII deficient patients with inhibitors? Haemophilia. 2015; 21:398-404. doi: 10.1111/hae.12578.
White NJ, Newton JC, Martin EJ, Mohammed BM, Contaifer D Jr, Bostic JL, Brophy GM, Spiess BD, Pusateri AE, Ward KR, Brophy DF. Clot Formation is Associated with Fibrinogen and Platelet Forces in a Cohort of Severely-Injured Emergency Department Trauma Patients. Shock. 2015;44 Suppl 1:39-44. doi: 10.1097/SHK.0000000000000342.
White NJ, Contaifer D Jr, Martin EJ, Newton JC, Mohammed BM, Bostic JL, Brophy GM, Spiess BD, Pusateri AE, Ward KR, Brophy DF. Early hemostatic responses to trauma identified with hierarchical clustering analysis. J Thromb Haemost. 2015 Jun;13(6):978-88. doi: 10.1111/jth.12919.
Voils SA, Martin EJ, Mohammed BM, Bayrlee A, Brophy DF. Laboratory assessment of warfarin reversal with global coagulation tests versus international normalized ratio in patients with intracranial bleeding. Blood Coagul Fibrinolysis. 2015; 26:443-7. doi: 10.1097/MBC.0000000000000270.
Poster presentation at The International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress and 61st Annual SSC Meeting, Toronto, Canada, June 20-25, 2015. Poster Num: PO273 Title: Coated Platelet Levels in severe hemophilia do not correlate to bleeding phenotype. Kelly L. Lastrapes, Bassem M. Mohammed, Erika J. Martin, Dougald M. Monroe, Maureane Hoffman, Melinda Nolte, Janice Kuhn, John C. Barrett, Donald F. Brophy.
Mangrum JB, Martin EJ, Brophy DF, Hawkridge AM. Intact stable isotope labeled plasma proteins from the SILAC-labeled HepG2 secretome. Proteomics. 2015 Sep;15(18):3104-15. doi: 10.1002/pmic.201400369.
Salinas V, Carmona R, Mohammed BM, Martin EJ, Brophy DF, Young G. Is some better than none: Are TEG and TGA profiles different in severe FVIII deficient patients with inhibitors? Haemophilia 2015; 21:398-404. doi: 10.1111/hae.12578.
Nweke C, Martin E, Gehr T, Brophy D, Carl D. Differences in coagulation in clotting of vascular access in hemodialysis patients. Hemodial Int. 2015; 19:323-9. doi: 10.1111/hdi.12241.
Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH; Hemophilia Inhibitor Research Study Investigators; Hemophilia Inhibitor Research Study Investigators. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. J Thromb Haemost. 2015; 13:47-53. doi: 10.1111/jth.12768.
Gunasekera D, Ettinger RA, Nakaya Fletcher S, James EA, Liu M, Barrett JC, Withycombe J, Matthews DC, Epstein MS, Hughes RJ, Pratt KP. Personalized Approaches to Therapies for Hemophilia (PATH) Study Investigators. Factor VIII gene variants and inhibitor risk in African American hemophilia A patients. Blood. 2015; 126:895-904. doi: 10.1182/blood-2014-09-599365.
Mohammed BM, Martin EJ, Salinas V, Carmona R, Young G, Brophy DF. Failure of corn trypsin inhibitor to affect the thrombin generation assay in plasma from severe hemophiliacs. J Thromb Haemost. 2014; 12:1558-61.
Mehta AY, Thakkar JN, Mohammed BM, Martin EJ, Brophy DF, Kishimoto T, Desai UR. Targeting the GPIbα binding site of thrombin to simultaneously induce dual anticoagulant and antiplatelet effects. J Med Chem. 2014; 57:3030-9. Epub 2014 Mar 25.
Brophy DF, Carl DE, Mohammed BM, Song J, Martin EJ, Bostic JL, Gehr TW. Differences in coagulation between hemodialysis and peritoneal dialysis. Perit Dial Int. 2014; 34:33-40. Epub 2013 Dec 1.
Geary MK, McGeady L, Dunn L, Pennick L, Johnson M, Stolfi A. The Demographics of the United States Hemophilia Treatment Center Social Workers: The Results of a National Survey. Haemophilia. 2014; 20:500-5. doi: 10.1111/hae.12354.
Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT; Haemophilia Inhibitor Research Study Investigators. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia. 2014; 20:230-7. doi: 10.1111/hae.12302.
Poster presentation at 2014 International Neurotrauma Society Meeting, Budapest, Hungary, March 14, 2014. Defining platelet function in polytrauma patients with traumatic brain injury upon admission to the emergency department. Brophy GM, Mohammed BM, White NJ, Martin EJ, Newton JC, Contaifer D, Song J, Reynolds P, Ward KR, Brophy DF
Poster presentation at Thrombosis and Hemostasis Summit of North America 2014., Chicago, IL, April 11, 2014. Prothrombin time is not associated with thrombin generation after prothrombin complex concentrate administration in patients with intracranial hemorrhage. Voils SA, Martin EJ, Bayrlee A, Brophy DF.
Poster presentation at Thrombosis and Hemostasis Summit of North America 2014., Chicago, IL, April 11, 2014. Comparison of baseline thromboelastography and thrombin generation assay in factor VIII deficient patients with and without inhibitors. Salinas VK, Brophy DF, Martin EJ, Cornell R, Young G.
Poster presentation at Thrombosis and Hemostasis Summit of North America 2014, Chicago, IL, April 11, 2014. Association of thromboelastography parameters with thrombin generation after prothrombin complex concentrate administration in patients with intracranial hemorrhage. Voils S, Martin EJ, Bayrlee A, Brophy DF.
Poster presentation at 8th Bari International Conference, Bari, Italy, October 3-5, 2014. Failure of corn trypsin inhibitor to affect the thrombin generation assay in hemophilia plasma. Roxana Carmona, Bassem Mohammed, Vanessa Salinas, Erika Martin, Guy Young, Donald Brophy, Richard KO.
Poster presentation at 8th Bari International Conference, Bari, Italy, October 3-5, 2014. Comparison of Baseline Thromboelastography and Thrombin Generation Assay in Factor VIII Deficient Patients with and Without inhibitors. Vanessa Salinas, Roxana Carmona, Bassem Mohammed, Erika Martin, Donald Brophy, Guy Young, Richard KO.
Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM; Hemophilia Inhibitor Research Study Investigators. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost. 2013; 11:1300-9. doi: 10.1111/jth.12259.
Pandey GS, Yanover C, Miller-Jenkins LM, Garfield S, Cole SA, Curran JE, Moses EK, Rydz N, Simhadri V, Kimchi-Sarfaty C, Lillicrap D, Viel KR, Przytycka TM, Pierce GF, Howard TE, Sauna ZE; PATH (Personalized Alternative Therapies for Hemophilia) Study Investigators. Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia. Nat Med. 2013; 19:1318-24. doi: 10.1038/nm.3270.
Al Hawaj MA, Martin EJ, Venitz J, Barrett JC, Kuhn JG, Nolte ME, Brophy DF. Haemophilia. Monitoring rFVIII prophylaxis dosing using global haemostasis assays. Haemophilia. 2013; 19:409-14. doi: 10.1111/hae.12110.
Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM; Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012; 10:1055-61. doi: 10.1111/j.1538-7836.2012.04705. x.
Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W; Hemophilia Inhibitor Research Study Investigators. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia. 2012; 18:375-82. doi: 10.1111/j.1365-2516.2011.02700. x.
Poster presentation at XXX International Congress of the World Federation of Hemophilia, Paris, France, July 8-12, 2012. Vitamin D improves bone health in patients with hemophilia. Gowda M, Kumar Ramaswamy A, Kuhn JG, Nolte ME, Martin EJ, Brown S, Willis J, Massey GV.
Poster presentation at XXX International Congress of the World Federation of Hemophilia, Paris, France, July 8-12, 2012. Characterizing global hemostasis throughout the FVIII prophylaxis dosing interval: A pilot study. AlHawaj M, Martin EJ, Barrett JC, Kuhn JG, Nolte ME, Brophy DF.
Poster presentation at XXX International Congress of the World Federation of Hemophilia, Paris, France, July 8-12, 2012. Pharmacokinetic-pharmacodynamic (PK/PD) modelling of factor VIII (FVIII) using its plasma concentration and global hemostasis biomarkers. AlHawaj M, Venitz J, Martin EJ, Barrett JC, Kuhn JG, Nolte ME, Brophy DF.
Brophy DF, Martin EJ, Barrett JC, Nolte ME, Kuhn JG, Pelzer H, Agersø H, Carr ME, Ezban M, Hedner U. Monitoring rFVIIa 90 µg Kg-1: Comparing Laboratory Response of Using Various Whole Blood Assays Over 6 h. Haemophilia. 2011; 17:949-57. doi: 10.1111/j.1365-2516.2011.02492. x.
Brophy DF, Martin EJ, Barrett JC, Nolte ME, Kuhn JG, Ezban M, Hedner U. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays. Blood Coagul and Fibrinolysis. 2011; 22:541-6. doi: 10.1097/MBC.0b013e328348d9e5.
Agersø H, Brophy DF, Martin EJ, Pelzer H, Carr ME, Hedner U, Ezban M. Factor VIIa cleared principally by antithrombin following IV administration in haemophilia patients. J Thromb Haemost. 2011; 9:333-8. doi: 10.1111/j.1365-2516.2011.02492. x.
Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Barrett JC, Ezban M. Factor VIIa analog (NN1731) has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A. Blood Coagul Fibrinolysis.2010;21:539-46. doi: 10.1097/MBC.0b013e32833b63e9.
Poster presentation at XXIX International Congress of the World Federation of Hemophilia, Buenos Aires, Argentina, July 10-14, 2010. Poster Num: 0473 Title: Using Global Hemostasis Laboratory Parameters to Identify rFVIIa Response. Brophy DF, Martin EJ, Ezban M, Hedner U, Carr ME, Barrett JC.
Poster presentation at XXIX International Congress of the World Federation of Hemophilia, Buenos Aires, Argentina, July 10-14, 2010. Poster Num: 0474 Title: Evaluation of Hemodyne HAS parameters in a patient with Hemophilia A and an inhibitor who has poor clinical response to standard dose rFVIIa. Brophy DF, Martin EJ, Barrett JC, Nolte, M, Kuhn, JG, Carr ME, Ezban M, Hedner U.
Henry BL, Thakkar JN, Martin EJ, Brophy DF, Desai UR. Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids. Blood Coagulation and Fibrinolysis. 2009; 20:27-3.
Brophy DF, Bukaveckas BL, Ferreira-Gonzalez A, Archer KJ, Martin EJ, Gehr, TWB. A pilot study of genetic polymorphisms and dialysis vascular access thrombosis. Hemodialysis Int. 2009; 13:19-26.
Poster presentation at National Kidney Foundation (NKF) 2009 Spring Clinical Meetings, Nashville, Tennessee, March 25-29, 2009. Blood Coagulation across the spectrum of chronic kidney disease. Brophy DF, Martin EJ, White NJ, Gehr TWB.
Poster presentation at XXII Congress of The International Society on Thrombosis and Haemostasis, Boston, MA, July 11-16, 2009. Poster Num: 245 Title: Effects of rFVIIa analogue (NN1731) on platelet function, clot structure and clot kinetics in whole blood from patients with hemophilia A. Brophy, Martin EJ, Nolte ME, Kuhn JG, Ezban M.
Poster presentation at American Society of Hematology 51st Annual Meeting, New Orleans, Louisiana, December 05 - 08, 2009. Abstract 3485: Blood 2009; Volume 114, issue 22, November 20, 2009. Title: Differences in Global Hemostasis Following rFVIIa Dosing: A Focus on Responders Versus Poor Responders. Brophy DF, Martin EJ, Barrett JC, Nolte, M, Kuhn, JG, Carr ME, Ezban M, Hedner U.
Poster presentation at American Society of Hematology 51st Annual Meeting, New Orleans, Louisiana, December 05 - 08, 2009. Abstract 1295: Blood 2009; Volume 114, issue 22, November 20, 2009. Title: Formation of FVIIa-Antithrombin Complexes After Administration of rFVIIa to Hemophilia Patients. Ezban M, Martin EJ, Barrett JC, Kuhn JG, Nolte M, Pelzer H, Agerso H, Petersen LC, Hedner U, Carr ME, Brophy DF.
Abstract in Academic Emergency Medicine 2008 2008;15(s1): S120. Title: Functional Analysis of Platelet Contraction and Clot Elastic Modulus during Hemorrhagic Shock. White NJ, Martin EJ, Ward KR.
Poster presentation at American Society of Hematology 52st Annual Meeting, Orlando, Florida, December 04 - 07, 2008. Abstract 4106: Blood 2008; Volume 112, issue 11, November 2008. Title: The Effect of Soluble P-Selectin in Coagulation. Korakas I, Guillen D, Martin EJ, Tranholm M, Barnett T, Li C.
Poster presentation at XXI Congress of The International Society on Thrombosis and Haemostasis, Geneva, Switzerland, July 6-12, 2007. Effects of Recombinant Factor VIIa Variant (NN1731) on Platelet Function, Clot Structure, and Force Onset Time in Blood from Healthy Volunteers and Hemophilia Patients. Brophy DF, Martin EJ, Nolte ME, Kuhn JG. Carr ME, Ezban M.
Brophy DF, Martin EJ, Carr SL, Kirschbaum B, Carr ME. The Effect of Uremia on Platelet Contractile Force, Clot Elastic Modulus and Bleeding Time in Hemodialysis Patients. Thromb Res. 2007; 119:723-9.
Brophy DF, Martin EJ, Nolte ME, Kuhn JG, Carr ME. Effect of Recombinant Factor VIIa Variant (NN1731) on Platelet Function, Clot Structure and Force Onset Time in Whole Blood from Normal Volunteers and Hemophilia Patients. Haemophillia. 2007; 13:533-41s.
Sterling RK, Lyons CK, Stravitz RT, Luketic VA, Sanyal AJ, Carr ME, Smith TJ, Hackney MH, Kontos MJ, Mills SA, Kuhn JG, Nolte ME, Schiffman M. Percutaneous liver biopsy in adult hemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease. Haemophilia, 2007, Mar; 13 (2), 164-171.
Brophy DF, Martin EJ, Gehr TWB, Best AM, Paul K, Carr ME. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. J Thromb Haemost. 2006; 4:372-6.
Brophy DF, Carr ME Jr, Martin EJ, Venitz J, Gehr TW. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies J Clin Pharmacol. 2006; 46:887-94.
Brophy DF, Martin EJ, Gehr TWB, Carr ME. A hypothesis-generating study to evaluate platelet activity in diabetics with chronic kidney disease. Thromb J. 2005; 3:3
Poster presentation at 38th Annual Meeting of the American Society of Nephrology. Philadelphia, PA, November 8, 2005. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in Stage 5 CKD patients. Brophy DF, Martin EJ, Gehr TWB, Carr ME.
Poster presentation at American Society of Hematology 47th Annual Meeting, Atlanta, Georgia, December 10 - 13, 2005. Abstract 4144: Blood 2005; Volume 106, issue 11, November 16, 2005. Correlation between Antifactor Xa Activity and Thrombin Generation Time, Platelet Contractile Force and Clot Elastic Modulus Following Enoxaparin Exposure in Patients with and without Renal Dysfunction. Brophy DF, Martin EJ, Gehr TWB, Best AM, Carr ME.
Poster presentation at American Society of Hematology 47th Annual Meeting, Atlanta, Georgia, December 10 - 13, 2005. Abstract 4033: Blood 2005; Volume 106, issue 11, November 16, 2005. Differential Dose Dependent Effects of Recombinant FVIIa and Enhanced Activity Analogue (NN1731) on Thrombin Generation, Platelet Function and Clot Structure in Blood from Normal Volunteers and Patients with Factor VIII Deficiency with or without Factor VIII Inhibitor Antibodies. Brophy DF, Martin EJ, Nolte ME, Kuhn J, Reddy S, Ezban M, Carr ME.
Carr ME, Ambrose HS, Martin EJ. Fibrin Sealants. Encyclopedia of Biomaterials and Biomedical Engineering. 2004; 2:611-620.
Brophy DF, Martin EJ, Gehr TWB, Carr ME. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex-vivo enoxaparin exposure in patients with and without renal dysfunction. J Thromb Haemostasis. 2004; 2:1299-1304.
Brophy DF, Martin EJ, Gehr TWB, Carr ME. Enhanced anticoagulant effect of enoxaparin in patients with end-stage renal disease as measured by thrombin generation time. Am J Kidney Dis. 2004 Jul; 44:270-277.
Carr ME, Martin EJ, Kuhn JG, Ambrose H, Fern S, Bryant PC. Monitoring of hemostatic status in four patients being treated with recombinant factor VIIa. Clin Lab. 2004; 50:529-538.
Car ME, Martin EJ. Evolving techniques for monitoring clotting in plasma and whole blood samples. Clin Lab. 2004; 50:539-49. Review.
M.E. Carr, E.J. Martin. Recombinant Factor VIIa: Clinical applications for an intravenous hemostatic agent with broad-spectrum potential. Expert Rev Cardiovasc Ther. 2004; 2:661-674. Review.
Oral presentation at the 2nd ACCP-ESCP International Congress on Clinical Pharmacy, Paris, 28-30 April 2004. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction. Brophy DF, Martin EJ, Best AM, Gehr TWB, Carr ME.
Poster presentation at the 2nd ACCP-ESCP International Congress on Clinical Pharmacy, Paris, 28-30 April 2004. Diabetic patients have increased platelet activity as measured by platelet contractile force and clot elastic modulus. Brophy DF, Martin EJ, Gehr TWB, Carr ME.
Poster presentation at the 46th Annual meeting of the American Society of Hematology, San Diego, CA, Dec 4-7, 2004. At 90 micrograms per kilogram, recombinant factor VIIa partially corrects abnormal hemostatic function in blood from factor IX deficient patients. Carr ME, Martin EJ, Kuhn JG, Nolte M.
Carr ME, Carr SL, Tildon T, Fisher LM, Martin EJ. Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies. Journal of Thrombosis and Haemostasis 2003; 1:243-249.
Carr ME, Kuhn JG, Martin EJ, Tidwell AR, Hagan MK. Pseudo-prolongation of the prothrombin time during treatment for bleeding with recombinant factor VIIa in a patient with a spontaneous Factor VIII inhibitor. International Journal of Hematology 2003; 77:308-309.
Carr ME, Martin EJ, Kuhn JG, Seremetis SV. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion. Thrombosis and Haemostasis 2003; 89:803-11.
Carr ME, Angchaisuksiri P, Carr SL, Martin EJ. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function and clot structure in whole blood. Cell Biochemistry and Biophysics. 2003; 39:89-99.
Carr ME, Martin EJ, Kuhn JG, Spiess BD. Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT). J Thromb Haemostasis. 2003; 1:1977-1983.
Poster presentation at the 45th Annual meeting of the American Society of Hematology, San Diego, CA, Dec 6-9, 2003. Blood 102 (11); 122b, 2003. An in vitro study of the correlation of changes in activated clotting time, platelet contractile force, and clot elastic modulus with low molecular weight heparin (Lovenox, Aventis) levels. Carr ME, Cornwell N, McCarthy HL, Spiess BD, Martin EJ.
Poster presentation at the 45th Annual meeting of the American Society of Hematology, San Diego, CA, Dec 6-9, 2003. Blood 102 (11); 104-105b, 2003. High dose recombinant activated factor VIIa in a pediatric patient with factor VIII deficiency and high titer inhibitor. J. Sutton, P. Bryant, M.E. Carr, E.J. Martin.
Poster presentation at the 2003 ACCP Annual Meeting, Atlanta, GA, November 3, 2003. Abstract 93. Pharmacotherapy 2003; 23:1342. Correlation between antifactor Xa activity, thrombin generation time, platelet contractile force, and clot elastic modulus following ex vivo enoxaparin exposure. Brophy DF, Martin EJ, Gehr TWB, Carr ME
Poster presentation at the 2003 ACCP Annual Meeting, Atlanta, GA, November 4, 2003. Correlation between antifactor Xa activity, thrombin generation time, platelet contractile force, and clot elastic modulus following ex vivo enoxaparin exposure. Brophy DF, Martin EJ, Gehr TWB, Carr ME.
Carr ME, Martin EJ, Carr SL. Delayed, reduced and inhibited thrombin production reduces platelet contractile force and results in weaker clot formation. Blood Coagulation and Fibrinolysis 2002; 13:193-197.
Greilich P, Brouse C, Beckham J, Jessen M, Martin E, Carr M. Reductions in platelet contractile force correlate with duration of cardiopulmonary bypass and blood loss in patients undergoing cardiac surgery. Thrombosis Research 2002; 105:523-529.
Carr ME, Krishnaswami A, Martin EJ. Platelet contractile force (PCF) and clot elastic modulus (CEM) are elevated in diabetic patients with chest pain. Diabetic Medicine 2002; 19:862-866.
Carr ME, Hackney MH, Hines SJ, Heddinger SP, Carr SL, Martin EJ. Enhanced platelet force development despite drug induced inhibition of platelet aggregation in patients with thromboangiitis obliterans. Vascular and Endovascular Surgery 2002; 36:473-480.
Krishnaswami A, Carr ME, Jessie RL, Kontos M, Minisi AJ, Ornato JP, Vetrovec GW, Martin EJ. Patients with coronary artery disease who present with chest pain have significantly elevated platelet contractile force and clot elastic modulus. Thrombosis and Haemostasis 2002; 88:739-44.
Carr ME, Carr SL, Martin EJ, Johnson BA. Rapid clot formation and abnormal fibrin structure in a symptomatic patient taking fenfluramine. Angiology 2001; 52:361-366.
Topaz O, Minisi AJ, Bernardo NL, McPherson RA, Martin E, Carr SL, Carr ME. Effect of Excimer Laser emission on platelet aggregation: the “stunned platelet” phenomenon. Thrombosis and Haemostasis 2001; 86:1087-1093.
Poster presentation at the 44th annual meeting of the American Society of Hematology, Philadelphia, PA, December 6-10, 2002. Blood 100 (Suppl 1):120b,2002. Title: Effect of non-heparin thrombin antagonists on whole blood thrombin generation, platelet function and clot structure. Carr ME, Angchaisuksiri P, Carr SL, Martin EJ.
Poster presentation at the 44th annual meeting of the American Society of Hematology, Philadelphia, PA, December 6-10, 2002. Blood 100 (Suppl 1):87b,2002. Title: Effects of recombinant factor VIIa on thrombin generation, platelet function and clot structure in blood with deficient prothrombin conversion. Carr ME, Martin EJ, Kuhn JG, Seremetis S.
Poster presentation at the 44th annual meeting of the American Society of Hematology, Philadelphia, PA, December 6-10, 2002. Blood 100 (Suppl 1):108b,2002. Title: Platelet contractile force and clot elastic modulus as markers of thrombin generation in a patient with severe factor VII deficiency undergoing treatment with recombinant factor VIIa. Carr ME, Kuhn JG, Martin EJ.
Poster presentation at the 34th annual meeting of the National Hemophilia Foundation. Orlando, FL, October 31-November 2, 2002. Pseudo-prolongation of the prothrombin time by recombinant factor VIIa in a patient being treated for bleeding secondary to a spontaneous factor VIII inhibitor. Carr ME, Kuhn JG, Martin EJ, Tidwell A, Hagan MK.
Oral presentation at the New Techniques for the Clinical Laboratory section of the Eighteenth Annual Hemostasis Update 2001 meeting of Temple University Hospital. Philadelphia, PA. April 26-28, 2001. Development of Platelet Contractile Force as a Platelet Specific Hemostatic Marker. Marcus E Carr Jr., Erika J. Martin.
Poster presentation at the XVIII Congress of The International Society on Thrombosis and Haemostasis, Paris, France, July 6-12, 2001. Poster Num: P375, Thrombosis and Haemostasis Supplement July 2001, P375. Elevated platelet contractile force (PCF) in diabetic patients – a potential marker of increased thrombotic risk. Carr M, Krishnaswami A, Martin E.
Poster presentation at the 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, Nov 30-Dec 4, 2001. Reductions in Platelet Contractile Force correlate with duration of cardiopulmonary bypass and blood loss in patients undergoing cardiac surgery. Greilich PE, Carr ME, Brouse C, Martin EJ, Beckham J, Augustus M, Estrera A.
Poster presentation at the 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, Nov 30-Dec 4, 2001. Delayed, reduced or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation. Carr ME, Martin EJ, Carr SL.
Poster presentation at the XVIIth Congress of the International Society for Thrombosis and Haemostasis. Washington, DC. Aug 14-21,1999. Thrombosis and Haemostasis (Supplement): 162, Aug 1999. Patients with coronary artery disease who present with chest pain have significantly elevated platelet contractile force. Krishnaswami A, Carr ME, Jesse RL, Kontos M, Minisi AJ, Ornato JP, Vetrovec GW, Martin EJ.
Poster presentation at the XVIIth Congress of the International Society for Thrombosis and Haemostasis. Washington, DC. Aug 14-21,1999. Thrombosis and Haemostasis (Supplement): 396, Aug 1999.Title: Reproducibility, daily variation, and the effect of sample age on platelet contractile force and clot elastic modulus in normal volunteers. Carr ME, Martin EJ.
Poster presentation at the 41st annual meeting of the American Society of Hematology, New Orleans, LA Dec 3-7, 1999. Blood 94 (Suppl 1):69b,1999. Platelet contractile force and clot elastic modulus are abnormal in high-risk chest pain patients in the emergency department. Krishnaswami A, Kontos MC, Martin EJ, Jesse RL, Vetrovec GW and Carr ME.
Poster presentation at the 41st annual meeting of the American Society of Hematology, New Orleans, LA Dec 3-7, 1999. Blood 94 (Suppl 1):63b,1999. In vitro addition of platelet activating factor to whole blood does not alter platelet contractile force. Carr ME, Martin EJ.
Poster presentation at the 41st annual meeting of the American Society of Hematology, New Orleans, LA Dec 3-7, 1999. Blood 94 (Suppl 1):117b,1999. How long does a platelet survive? Platelet contractile force as a measure of platelet viability. Carr ME, Martin EJ.